Variables | Studies (n) | Patients (n) | p-value | Incidence | ||
---|---|---|---|---|---|---|
Mean difference (95 % CI) or risk ratio (95 % CI) | Heterogeneity p-value (I2) | Model | ||||
24 h cumulative consumption | ||||||
Overall | 5 | 540 | <0.001 | −7.82 (−0.95, −0.52) | <0.001 (87.2 %) | random |
Gabapentin | 3 | 300 | <0.001 | −2.65 (−3.67, −1.63) | 0.427 (0 %) | random |
Pregabalin | 2 | 240 | <0.001 | −19.42 (−11.72, −3.93) | <0.001 (59.9 %) | random |
48 h cumulative consumption | ||||||
Overall | 5 | 378 | 0.118 | −6.90 (−0.95, 0.57) | <0.001 (93.7 %) | random |
Gabapentin | 3 | 258 | 1.000 | 0.00 (−7.69, 7.69) | <0.001 (94.5 %) | random |
Pregabalin | 2 | 120 | <0.001 | −33.02 (−45.86, −20.19) | 0.989 (0.00 %) | random |
VAS score with rest at 24 h | ||||||
Overall | 5 | 451 | 0.360 | 0.15 (−0.17, −0.48) | 0.017 (63.7 %) | random |
Gabapentin | 3 | 300 | 0.076 | 0.32 (−0.03, 0.67) | 0.082 (55.3 %) | random |
Pregabalin | 2 | 151 | 0.486 | −3.05 (−11.63, 5.53) | 0.193 (41.1 %) | random |
VAS score with rest at 48 h | ||||||
Overall | 3 | 331 | 0.363 | 0.22 (−0.25, 0.69) | 0.003 (78 %) | random |
Gabapentin | 2 | 258 | 0.049 | 0.41 (0.00, 0.81) | 0.072 (62.1 %) | random |
Pregabalin | 1 | 73 | 0.106 | NS | NS | NS |
VAS score with mobilization at 24 h | ||||||
Overall | 5 | 451 | 0.164 | 0.46 (−0.19, 1.11) | <0.001 (91 %) | random |
Gabapentin | 3 | 300 | 1.137 | 0.72 (0.23, 1.66) | <0.001 (93.1 %) | random |
Pregabalin | 2 | 151 | 0.803 | −0.78 (−6.91, 5.35) | 0.799 (0 %) | random |
VAS score with mobilization at 48 h | ||||||
Overall | 3 | 331 | 0.193 | 1.15 (−0.58, 2.89) | <0.001 (97.8 %) | random |
Gabapentin | 2 | 258 | 0.045 | 1.90 (0.04, 3.75) | <0.001 (97.2 %) | random |
Pregabalin | 1 | 73 | <0.001 | NS | NS | NS |